Results 171 to 180 of about 150,246 (305)

Imaging-Pathology Discordance During Neoadjuvant Chemotherapy for Pediatric Osteosarcoma. [PDF]

Pediatr Int
Ito J, Narukama R, Aibara Y, Nakayama R, Yamazaki F.   +4 more
europepmc   +1 more source

Neoadjuvant chemotherapy in invasive bladder cancer

, 2005
The role of neoadjuvant chemotherapy in muscle-invasive bladder cancer has been clarified by recent randomized studies and meta-analyses, which all showed that cisplatin-based, combination chemotherapy offers a significant survival advantage ...
Bamias, Aristotle, Dimopoulos, Meletios A., Dimopoulos, Meletios A   +2 more
core  

α2,3‐Sialyltransferase (ST3Gal1) regulates endometrioid‐type epithelial ovarian cancer cell migration and invasion via VEGF‐R2/JAK2/STAT3 signaling cascades

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To investigate the role of ST3 β‐galactoside α‐2,3‐sialyltransferase 1 (ST3Gal1) and vascular endothelial growth factor receptor 2 (VEGF‐R2) in endometrioid‐type epithelial ovarian cancer (E‐OC) because aberrant α2,3‐sialylation mediated by ST3Gal1 and VEGF‐R2‐related angiogenesis is linked with tumor progression. Methods ST3Gal1 and
Wei‐Ting Chao, Chia‐Hao Liu, Szu‐Ting Yang, Chen‐Hao Lin, Liang‐Wei Wang, Peng‐Hui Wang   +5 more
wiley   +1 more source

Angiotensin inhibitors during neoadjuvant chemotherapy improve esophageal squamous cell carcinoma outcomes. [PDF]

Ther Adv Med Oncol
Chen M, Huang Y, Liu F, Lin C, Zhang S, Zeng T, Yu J, Zheng B, Chen C.   +8 more
europepmc   +1 more source

The role of human microbiota in breast cancer pathogenesis and treatment

iMeta, EarlyView.
The human microbiota contributes to breast cancer pathogenesis and treatment response through interactions involving the oral, gut, and breast microbial niches. (Left) Multi‐site dysbiosis is characterized by altered microbial composition and abundance across different anatomical sites.
Jie Qiu, Xiaojia Wang, Man Li, Jing Guo, Shipeng Ning, Yi‐Zhou Gao, Xinyi Zhang, Xuli Meng, Yiding Chen, Yunxiang Zhou   +9 more
wiley   +1 more source

Immune-metabolic profiling of triple-negative breast cancer during neoadjuvant chemotherapy. [PDF]

iScience
Shi R, Pang Y, Chen C, Liu K, Wang W, Shang Y, Li Z, Ren H, Wang W.   +8 more
europepmc   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

Liver transplantation in unresectable intrahepatic cholangiocarcinoma following neoadjuvant chemotherapy and SIRT. [PDF]

JHEP Rep
Giguet B, Artru F, Jeddou H, Houssel-Debry P, Jegonday MA, Coirier V, Jezequel C, Chebaro A, Robin F, Boudjema K, Rolland Y, Garin E, Beuzit L, Turlin B, Bardou-Jacquet E, Edeline J, Uguen T.   +16 more
europepmc   +1 more source

Black phosphorus‐based photothermal disruption of cancer‐associated fibroblast barriers and tumor‐associated macrophage targeting to enhance anti‐PD‐L1 immunotherapy in triple‐negative breast cancer

Interdisciplinary Medicine, EarlyView.
MBB modulates the TNBC tumor microenvironment by targeting TAM/CXCL1 and facilitates anti‐PD‐L1 therapy by disrupting CAF barriers via its photothermal effect. This combined strategy subsequently enhances the efficacy of PD‐L1 mAb and suppresses TNBC progression, metastasis, and recurrence.
Bo Pan, Shicui Hong, Xinyue Wang, Yanghang Li, Cai Wang, Yaxiao Liu, Ying Chen, Chen Fang, Yifeng Zheng, Shengqi Wang, Juping Zhang, Neng Wang, Zhiyu Wang   +12 more
wiley   +1 more source

Omission of axillary dissection in patients with microscopic residual nodal disease after neoadjuvant chemotherapy. [PDF]

Gland Surg
Noguchi M, Inokuchi M, Morioka E, Haba Y.   +3 more
europepmc   +1 more source